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Safety of sublingual-swallow immunotherapy in
children aged 3 to 7 years
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and Franco Frati, MD
Background: The minimum age to start specific immunotherapy with inhalant allergens in children has not been clearly
established, and position papers discourage its use in children younger than 5 years.
Objective: To assess the safety of high-dose sublingual-swallow immunotherapy (SLIT) in a group of children younger than
5 years.
Methods: Sixty-five children (51 boys and 14 girls; age range, 38–80 months; mean  SD age, 60  10 years; median age,
60 months) were included in this observational study. They were treated with SLIT with a build-up phase of 11 days, culminating
in a top dose of 300 IR (index of reactivity) and a maintenance phase of 300 IR 3 times a week. The allergens used were house
dust mites in 42 patients, grass pollen in 11 patients, olive pollen in 5 patients, Parietaria pollen in 4 patients, and cypress pollen
in 3 patients. All adverse reactions and changes in the treatment schedule were compared in 2 subgroups: children 38 to 60
months old and children 61 to 80 months old.
Results: The average cumulative dose of SLIT was 36,900 IR. Adverse reactions were observed in 11 children, none of them
severe enough to require discontinuation of immunotherapy. Six reactions occurred in the 60 months or younger age group and
7 in the older than 60 months age group, with no differences between these 2 groups.
Conclusion: High-dose immunotherapy in children younger than 5 years does not cause more adverse reactions than in
children aged 5 to 7 years. There is no reason to forbear studies on safety and efficacy of these preparations in young
children.
Ann Allergy Asthma Immunol. 2005;95:254–258.
INTRODUCTION
Concerns over adverse reactions and compliance have led to
the development of sublingual-swallow immunotherapy
(SLIT) as distinct from, and in addition to, the subcutaneous
administration of allergy vaccines.1–3 SLIT is gaining clinical
acceptance, although no consensus exists regarding its effi-
cacy.4 SLIT has been proposed as particularly appropriate and
safe for children,5 but few safety data have targeted pediatric
populations.6–10 Safety is often deduced from studies that
include children but do not report their ratio to adult pa-
tients.11–15 Few studies include children younger than 5
years.6,7,16
The 1993 European Academy of Allergology and Clinical
Immunology position paper advises avoidance of immuno-
therapy for children younger than 5 years.17 Thus, European
health care professionals have been reluctant to prescribe
specific immunotherapy in very young children.18 However,
the 1998 World Health Organization position paper merely
lists age for initiation of immunotherapy among “research
needs” and advises specialist evaluation.19 The 2001 Allergic
Rhinitis and Its Impact on Asthma (ARIA) Workgroup and
World Health Organization document states that immuno-
therapy, including SLIT, should be initiated early in the
disease process, but minimum age for onset of treatment is
not specified.20 The 2003 Joint Task Force position paper of
the American College of Asthma, Allergy and Immunology
and the American Academy of Allergy, Asthma and Immu-
nology mentions age at onset of immunotherapy as a clinical
problem of “cooperation.”21 Thus, the position that “there is
no absolute cut-off . . . with respect to the youngest age at
which allergen immunotherapy should be considered” re-
mains an open-ended research question.22 In clinical practice,
however, prescription of specific immunotherapy is gaining
ground in pediatrics. In many regions of Italy, allergy vac-
cines are supplied free of charge and immunotherapy is
administered in hospital for a minimal fee. Thus, the number
of young children receiving immunotherapy is increasing in
the absence of evidence-based restraints to prescriptions. In
this context, we designed a pilot study to evaluate during a
1-year period whether the 5-year cutoff point is relevant in
terms of safety for children aged 3 to 7 years already receiv-
ing SLIT for asthma and/or rhinoconjunctivitis.
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PATIENTS AND METHODS
Design
The study was designed as an observational, multicenter,
minimization study of SLIT prescribed for the treatment of
rhinoconjunctivitis and/or asthma in children younger than 7
years. Selection criteria balanced a number of diagnostic,
clinical, and prognostic factors obtained from a question-
naire.23,24 Entry criteria were as follows: age between 36 and
84 months, monosensitization to pollen or mite allergen,
intermittent-severe or persistent rhinoconjunctivitis according
to ARIA criteria or level I or II allergic asthma according to
the Global Initiative for Asthma (GINA) criteria or both
rhinoconjunctivitis and asthma, and pharmacologic medica-
tion appropriate to each GINA and ARIA staging. Parents
were instructed to use the following rescue medications: for
rhinitis, nasal fluticasone, 50 g (Flixonase, GlaxoSmith-
Kline, Uxbridge, England) as a nasal spray; for conjunctivitis,
levocabastine, 0.5 mg/mL (Livostin, Jansen-Cilag, Birkerød,
Denmark) as ocular drops; and for asthma symptoms, salbu-
tamol (Ventolin, GlaxoSmithKline) as metered-dose inhaler.
The research question was whether children younger than 5
years have an increase in adverse events with a high dose of
SLIT. The primary outcome was the occurrence and the
severity of adverse reaction irrespective of triggering dose or
phase of treatment (either build-up or maintenance).
Patients
Children were recruited among outpatients who attended the
pediatric departments of Milan, Messina, Palermo, Salerno,
and Perugia, Italy, between January and December 2002, and
observation was continued for at least 1 year until December
2003. Children younger than 84 months at the onset of SLIT
were selected according to the minimization criteria listed
herein. Diagnosis and staging were performed by a pediatric
allergist with the exclusion of relevant nonallergic triggers of
rhinitis and asthma. After selection, parents of patients gave
written informed consent. The study was approved by the
ethical committees of participating centers.
SLIT Schedules
Children were treated with Staloral 300 (Stallerge`nes,
Antony, France). The allergen extract was graded into con-
centrations of 1, 10, 100, and 300 IR (index of reactivity) per
milliliter. The IR is a unit of allergenic activity specific to the
Stallerge`nes laboratory: a 100-IR extract is defined by its
capacity to induce a mean wheal diameter of 7 mm in skin
prick tests in a panel of 30 patients sensitized to the allergen
considered. The build-up phase was performed as suggested
by the manufacturer in 11 days with a top dose of 300 IR, and
the maintenance phase dose was 300 IR 3 times a week.
Drops were deposited under the tongue and held for 1 minute
before being swallowed.
Safety
Adverse reactions and changes in treatment schedule were
recorded by means of an ad hoc questionnaire. Reaction
severity was classified according to a 0- to 5-point scale
(Table 1).25 For the purpose of analysis, clinicians were
allowed to rank the different reaction types as reported in
Table 2. Phase of treatment (build-up or maintenance), dose
that elicited the adverse reaction, and the interval between
dose and reaction were recorded.
Statistical Analysis
Hypotheses were tested by the Fisher exact test, the null
hypothesis being that the median adverse event scores of the
children who participated in the intervention would not
change because of SLIT before or after 60 months. Data were
expressed as nominal categories on a binomial scale, and the
distribution of adverse effects by age was analyzed by the
binomial test.
RESULTS
Sixty-five children (14 girls and 51 boys; age range, 38–80
months; mean  SD age, 60  10 months; median age, 60
months) were observed. They were divided into 2 subgroups:
38 to 60 months (6 girls and 27 boys; mean  SD age at
onset, 52  6.0 months) and 61 to 80 months (8 girls and 24
boys; mean SD age at onset, 70 10.6 months). The mean
duration of treatment was 246  161 days. The average
cumulative dose of SLIT in the study population was
36,900  1,872 IR (36,200  1,227 for the group 5 years or
younger and 37,600  2,142 in the older group). Extracts
used were house dust mites in 42 patients, grass in 11 pa-
tients, olive tree in 5 patients, Parietaria in 4 patients, and
cypress pollens in 3 patients.
In the present series, SLIT, administered with a cumulative
dose more than 300 times higher than the standard dose
recommended with subcutaneous immunotherapy, was toler-
ated without adverse events in 54 of 65 cases, whereas 11
patients experienced 13 adverse reactions. Table 3 lists reac-
tions according to patient age in the 2 groups: 6 reactions
were recorded in 5 patients in the group of patients who
started treatment 60 months or younger and 7 reactions were
recorded in 6 patients in the group older than 60 months. Six
Table 1. Assessment of the Severity of Adverse Reactions by a 5-
Point Scale
Reaction Score
No reaction 0
Mild reaction (not requiring medical attention) 1
Mild-to-moderate reaction (requires medical care but
neither drug treatment nor modification of SLIT
schedule)
2
Moderate reaction (requires either SLIT schedule
modification or drug treatment)
3
Moderate-to-severe reaction (requires both drug
treatment and temporary interruption of SLIT
schedule)
4
Severe reaction (requires emergency department visit or
hospitalization)
5
Abbreviation: SLIT, sublingual-swallow immunotherapy.
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reactions occurred in the build-up phase and 7 in the main-
tenance phase, all ranging from mild to moderate and not
requiring SLIT cessation. Adjustments were necessary in 9
cases with the conventional schedule and in 2 (moderate
reaction) with a reduced maintenance dose. Reactions in the
maintenance phase occurred 40 to 350 days from onset of
SLIT. Dust mite allergen, used in 64.6% of programs, was
responsible for 76.9% of adverse reactions. The occurrence of
adverse reactions was independent of age (2  0.0348). The
magnitude of adverse effects is illustrated by the joint prob-
ability by age of 5 years or younger according to the multi-
plication rule. Among children 60 months or younger, these
probabilities were 0.08 and 0.11 in older children. Analysis of
the binomial distribution reveals that the probability of an
adverse outcome for a single patient is similar 60 months or
younger (0.16; SD, 2.34) and older than 60 months (0.17; SD,
2.20).
DISCUSSION
This is the first study, to our knowledge, to evaluate whether
a 5-year age limitation is clinically justified on safety grounds
among children receiving SLIT for asthma and allergic rhi-
nitis. In the literature, no absolute prohibition has been linked
to a rationale based on a risk increase in patients younger than
this age. Caution is recommended in the evaluation of the
tradeoffs of immunotherapy for individual patients. However,
this 5-year watershed may be a deterrent to the prescription of
SLIT at the very age when the allergic march starts and when
the early diagnosis of atopy should be made.26,27 Furthermore,
a preventive effect of specific immunotherapy on the natural
history of allergic disease may be lost with later onset of
therapy.28,29
We did not set out to evaluate the safety of SLIT in young
children, but evaluated young Italian children who received
SLIT as part of the management of their asthma or rhinocon-
junctivitis irrespective of the reason why SLIT had been
prescribed. This particular formulation has been proven ef-
fective in children.23 Thus, adverse events in response to
individual allergens were not evaluated. The main result of
this study was that on either side of the 5-year cutoff there
was no significant difference in occurrence of adverse reac-
tions. This finding suggests that younger age does not rule out
contemplating the prescription of SLIT when clinically indi-
cated. The few adverse reactions that occurred were low in
severity. No major clinical differences occurred among these
unselected children across the 60-month age limit during a
1-year period of observation. In this series, the unweighted
frequency of adverse reactions was 16.9%, which agrees with
the findings from selected populations studied under placebo-
Table 3. Adverse Reactions and Severity in 11 Children
Patient
No.
Allergen used
for SLIT
Treatment phase
Age,
mo
Symptom Severity
Time to
adverse
event, min
Children <60 months old
1 Grass Build-up 46 Urticaria 2 30
2 Grass Build-up 57 Urticaria 1 30
3 Cypress Maintenance 58 Gastrointestinal (colic) 2 30–60
4 Mites Build-up 59 Urticaria 2 30–60
Maintenance Urticaria 3 60
5 Mites Maintenance 59 Orolabial itch 2 30
Children >60 months old
6 Mites Maintenance 64 Gastrointestinal (colic) 3 30–60
7 Mites Maintenance 69 Gastrointestinal (vomit) 4 30–60
8 Mites Build-up 74 Urticaria 2 30
9 Mites Build-up 74 Urticaria 2 30–60
10 Mites Build-up 75 Orolabial itch 1 30
Maintenance Orolabial itch 1 30
11 Mites Maintenance 78 Gastrointestinal (colic, diarrhea) 3 30
Abbreviation: SLIT, sublingual-swallow immunotherapy.
Table 2. Questionnaire for the Evaluation of Adverse Reactions and
Severity Rank for Each Item
Adverse reaction Severity rank
None 0
Local adverse reaction
Orolabial itching 0–2
Labial edema 0–3
Nausea and vomiting 0–4
Colic, diarrhea 0–4
Respiratory adverse reaction
Rhinitis 0–4
Cough 0–4
Asthma 0–5
Cutaneous adverse reaction
Eczema 0–4
Urticaria 0–5
Angioedema 0–5
Other (specify) 0–5
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controlled conditions among whom the rate of adverse reac-
tions to SLIT was 6.25%13 to 49%.14
Treatment with SLIT with house dust mites, the build-up
phase, and errors in dosage and compliance are among the
risk factors for systemic reactions associated with subcutane-
ous immunotherapy. The waiting period following injection
has been set at 30 minutes, because most untoward reactions
tend to be immediate.17,30 In our series, most adverse effects
occurred after SLIT with house dust mites, and 53.8% of
reactions occurred during the build-up phase, underscoring
the critical clinical point represented by this stage of SLIT.
All but 1 reaction occurred within 60 minutes of administra-
tion, suggesting another critical clinical phase. All these
findings are reminiscent of data from the literature on sub-
cutaneous immunotherapy.
The limits of the present study are those of an observa-
tional study of adverse effects, because we could not, by
design, evaluate the clinical effects of SLIT in an unselected
population of children. Our aim was to examine the situation
during a 1-year period in the sociomedical Italian context,
where allergy vaccines are more readily available for pre-
scription.
Our data suggest that there is no reason to forbear assessing
safety and efficacy of SLIT beyond this pilot study on ac-
count of age of 5 years or younger. Because the efficacy of
specific immunotherapy is said to be higher among younger
children,18 further well-controlled clinical studies are needed
to establish the safety of SLIT among toddlers. These studies
should also address the clinical relevance of single allergens
as risk factors.
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